FDA approves Lupin Pharmaceuticals' Imipramine Pamoate capsules

Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Imipramine Pamoate capsules, 75 mg, 100 mg, 125 mg and 150 mg strengths.  Commercial shipments of the product have already commenced.

Lupin's Imipramine Pamoate capsules are the AB-rated generic equivalent of Mallinckrodt's *Tofranil-PM®.  Imipramine Pamoate capsules had annual sales of approximately $39 million for the twelve months ended December 2009, based on IMS Health sales data.


Source:

Lupin Pharmaceuticals, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Accelerating tobacco decline could boost global life expectancy